A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL-Reference-Cited by-同舟云学术

A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL

Published:2008-08-14 Issue:3 Volume:88 Page:221-227
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Decker Thomas,Sandherr Michael,Goetze Katharina,Oelsner Madlen,Ringshausen Ingo,Peschel Christian

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-008-0582-9.pdf

Reference32 articles.

1. Cheson BD, Bennett JM, Grever M et al (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87:4990–4997

2. Reed JC (1998) Molecular biology of chronic lymphocytic leukemia. Semin Oncol 25:11–18

3. Messmer BT, Messmer D, Allen SL et al (2005) In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 115:755–764

4. Ghia P, Circosta P, Scielzo C et al (2005) Differential effects on CLL cell survival exerted by different microenvironmental elements. Curr Top Microbiol Immunol 294:135–145

5. Schmid C, Isaacson PG (1994) Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study. Histopathology 24:445–451 doi: 10.1111/j.1365–2559.1994.tb00553.x

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Experiences with Drugs Targeting m TOR;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

2. Potentials of miR-15/16 targeting cancer stem cell pathways: Novel implication in cancer chemotherapy;Gene Reports;2020-09

3. Regulation of Hematopoietic Stem Cell Fate and Malignancy;International Journal of Molecular Sciences;2020-07-06

4. Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms;Exploration of Targeted Anti-tumor Therapy;2020-02-29

5. mTORC1/2 Inhibitor Served as a More Ideal Agent Against the Growth of Mouse Lymphocytic Leukemia Both In Vitro and In Vivo;Anticancer Research;2019-09